Celcuity Flips to Commercial: Revtopik Approval and a Launch Under a Mixed Tape
FDA green light for the PAM inhibitor is here, but the stock is off 35% from its peak — the story is now execution, pricing, and the mutant expansion.
CELC · Earnings Call · 2026-08-13
From Clinical to Commercial: The Revtopik Inflection
Less than a month after the FDA approved Revtopik (gedatolisib) for PIK3CA wild-type HR+/HER2- advanced breast cancer, Celcuity is already executing the final steps of a long-planned commercial launch. The company has completed its 80-person oncology sales force, submitted payer dossiers, and opened an expanded access program. Yet the equity tells a different story: the stock sits 35% below its May peak, down over 20% in the last 90 days, even as the catalyst that defined the past two years has arrived. That tension — between a game-changing approval and a de-risked tape — is the heart of this quarter's update. Management's confidence is unequivocal: “We remain on track to begin shipping Revtopik late in the third quarter of '26.” — Brian F. Sullivan, Chief Executive Officer · 2026-08-13 The Revtopik commercial engine is now being turned on, and the company is already looking past the wild-type label to the mutant expansion that could double its addressable population.Pricing Power and Gross-to-Net Strategy
At a wholesale acquisition cost of $10,000 per vial and $30,000 per cycle, Revtopik is priced as a premium medical benefit drug. Management expects a gross-to-net of ~80%, better than oral therapies in the class. On the call, Brian Sullivan detailed the economics: “we expect a gross to net percentage to be about 80%... the discounts involved from WACC will be about 20%.” — Brian F. Sullivan, Chief Executive Officer · 2026-08-13 This is a deliberate contrast to the 30% discount typical of oral PI3K inhibitors, a point that was already being telegraphed a year ago. Back in 2025, management noted that the medical benefit route could preserve pricing power: “medical benefit drugs like Geda would probably only have a 20% discount.” — Brian F. Sullivan, Chief Executive Officer · 2025-11-12 The execution risk now is not the price, but the conversion of that pricing into reimbursed patient starts. The company is also leveraging an expanded access program to bridge patients without interruption, and has begun shipping to physicians' offices. As Sullivan explained when asked about the program: “we have already begun shipping drug to physician or to sites where physicians are treating patients.” — Brian F. Sullivan, Chief Executive Officer · 2026-08-13 The transition to commercial supply will be carefully managed to avoid gaps in therapy.Pipeline Catalysts Beyond the Wild-Type Launch
While the launch is the near-term focus, the company is three steps ahead. The positive PIK3CA mutant cohort from VIKTORIA-1 has already generated a statistically significant PFS benefit over alpelisib, and a supplemental NDA is expected in Q3 2026. The company is also expanding the VICTORIA-2 trial to include endocrine-sensitive, treatment-naive patients — a move that positions gedatolisib as a first-line backbone. This broadens the PAM pathway story far beyond the initial wild-type label. Prostate cancer remains an optionality play. The dose-escalation portion is progressing, and the company expects to present data and a clear Phase 2 strategy in Q4. Management's view on the pathway's potential is consistent: “we believe, you know, that they demonstrate that this pathway, the PAM pathway, plays a role as a driver.” — Brian F. Sullivan, Chief Executive Officer · 2026-08-13 That PAM pathway positioning gives Celcuity a platform story, not just a single-asset drug.Financial Cost of Becoming Commercial
The commercial transformation is expensive. SG&A jumped to $35M in Q2, up from $7.6M a year ago, as the company built out its launch infrastructure. R&D spending remains elevated as clinical trials continue. Net loss widened to $78.9M for the quarter, though the convertible offering has extended the cash runway well into 2029. R&D expense is now $33M per quarter, up from under $2M a year ago. The company's cash position of $754M at quarter-end provides substantial runway, but the stock's 35% drawdown suggests the market is pricing in execution risk rather than the approval itself.That confidence will be tested in the fall, as the company transitions from clinical data to commercial revenue. The tape will be watching patient starts, gross-to-net realization, and the pace of sNDA review. If Revtopik's launch resonates, the stock's current discount to its own catalysts could close quickly; if not, the drawdown may persist. Celcuity has crossed the threshold from biotech to fully integrated oncology company. The story now is less about the science and more about the execution — and the market is already voting with its feet.we want to have confidence that our review process with the FDA will proceed according to what we expect to occur, that there are no surprises. And we are very confident about being able to ship beginning at the end of this quarter.